Upcoming Earnings: Q2 '26
Estimated EPS
-$0.10
Estimated Rev
$1.12M
$HUMA Q1 '26 Earnings Results & Recap Humacyte reduced its expected spending by $14.3M for the remainder of 2026 and reorganized its team, resulting in a reduction of total headcount by approximately 25% to focus resources on commercialization.
Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q2 '26 | -$0.10 | -- | -- | N/A |
Q1 '26 | -$0.12 | -$0.09 | 22.20% | BEAT |
Q4 '25 | -$0.13 | -$0.13 | 3.60% | BEAT |
Q3 '25 | -$0.15 | -$0.11 | 27.17% | BEAT |
Q2 '25 | -$0.16 | -$0.24 | -48.35% | MISSED |